Document is current
Any future updates will be listed below
-
Authors
Nakayama, Hirokazu http://orcid.org/0000-0001-9758-8004
Iizuka, Hiromitsu
Kato, Toshiaki
Usuki, Kensuke
- License Information
-
More Information
Article History
Received: 4 October 2022
Accepted: 23 December 2022
First Online: 23 January 2023
Declarations
:
: The protocol of the present study was approved by the Ethics Committee of NTT Medical Center Tokyo (approval number 19 − 380) prior to study commencement.The requirement of written informed consent from patients was waived due to the retrospective nature of the present study. Data used were obtained from routine medical care. The study was conducted with full consideration for protection of patients’ personal information, according to privacy policy guidelines.
: Not applicable
: HN and HI declare no conflicts of interest.TK has served on speakers’ bureaus for AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Elmed Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd and Yakult Honsha Co., Ltd.KU has received research funding from and served on speakers bureaus for the following incorporations.
